Today's Law As Amended


PDF |Add To My Favorites |Track Bill | print page

SB-252 Toxicological testing on dogs and cats.(2021-2022)



As Amends the Law Today


SECTION 1.
 This measure shall be known, and may be cited, as the Protection of Dogs and Cats from Unnecessary Testing Act.

SEC. 2.

 Section 1834.9.3 is added to the Civil Code, immediately following Section 1834.9, to read:

1834.9.3.
 (a) For purposes of this section, the following terms have the following meanings:
(1) “Alternative test method” means a test method that does not use animals, or in some cases reduces or refines the use of animals, for which the reliability and relevance for a specific purpose has been established by validation bodies, including, but not limited to, the Interagency Coordinating Committee for the Validation of Alternative Methods and the Organisation for Economic Co-operation and Development. Alternative test methods include, but are not limited to, high-throughput screening methods, testing of categories of chemical substances, tiered testing methods, in vitro studies, and systems biology.
(2) “Cat” means a small domesticated carnivorous mammal that is a member of the family Felidae, order Carnivora.
(3) “Canine or feline toxicological experiment” means any test or study of any duration that seeks to determine the effect, if any, of the application or exposure, whether internal or external, of any amount of a chemical substance on a dog or cat. “Application or exposure” includes, but is not limited to, oral ingestion, skin or eye contact, or inhalation. “Application or exposure” does not include testing of veterinary products for canine or feline health.
(4) “Chemical substance” means any organic or inorganic substance, including, but not limited to, a drug, as defined in Section 321(g) of Title 21 of the United States Code as that section read on January 1, 2021, a pesticide, as defined in Section 136(u) of Title 7 of the United States Code as that section read on January 1, 2021, a chemical substance, as defined in Section 2602(2) of Title 15 of the United States Code as that section read on January 1, 2021, or a food additive, as defined in Section 321(s) of Title 21 of the United States Code as that section read on January 1, 2021.
(5) “Dog” means any member of the species Canis familiaris.
(6) “Testing facility” means any partnership, corporation, association, school, institution, organization, or other legal relationship, whether privately or government owned, leased, or operated, that tests chemicals, ingredients, product formulations, or products in this state.
(b) Notwithstanding any law, and in addition to the prohibitions set forth in Sections 1834.9 and 1834.9.5, a testing facility shall not conduct a canine or feline toxicological experiment in this state unless the experiment is conducted for any of the following purposes:
(1) Medical research, including research related to the development of any vaccine, as defined under Section 4132(a)(2) of Title 26 of the United States Code as that section read on January 1, 2021, and research related to the development of biomedical products or devices, as defined under Section 321(h) of Title 21 of the United States Code as that section read on January 1, 2021. Medical research related to the development of drugs, as defined in Section 321(g)(1) of Title 21 of the United States Code as that section read on January 1, 2021, is not subject to this exemption unless it meets the requirements outlined in paragraph (3).
(2) To comply with federal requirements pertaining to the approval or maintenance of a medical device, as defined under Section 321(h) of Title 21 of the United States Code.
(3) To achieve discovery, approval, or maintenance of a drug, when required by federal law or directed by writing by the United States Food and Drug Administration (FDA) under Section 505 or 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355 et seq. and 21 U.S.C. Sec. 360 et seq.) or Sec. 351 of the Public Health Service Act (42 U.S.C. Sec. 262 et seq.) or any binding agency regulation promulgated upon notice and comment thereunder, if the FDA has not otherwise expressly authorized drug manufacturers to use alternative test methods.
(4) To achieve discovery, approval, registration, licensing, or maintenance of a biologic, pursuant to a testing requirement imposed by the United States Department of Agriculture (USDA) under the Virus-Serum-Toxin Act (21 U.S.C. Sec. 151 et seq.) or any binding agency regulation promulgated upon notice and comment thereunder, if the USDA has not concluded that waivers shall be granted for the experimentation or studies or expressly indicated acceptance of alternative test methods.
(5) To achieve discovery, approval, registration, or maintenance of a pesticide, pursuant to a testing requirement imposed by the United States Environmental Protection Agency (EPA) pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. Sec. 136 et seq.) or any binding agency regulation promulgated upon notice and comment thereunder, if the EPA has not concluded that waivers shall be granted for such experimentation or studies or expressly indicated acceptance of alternative test methods.
(6) To comply with a requirement to conduct the experiment under the Toxic Substances Control Act (15 U.S.C. Sec. 2601 et seq.), if the EPA has not, pursuant to Section 2603(h) of Title 15 of the United States Code, concluded that waivers shall be granted for such experimentation or studies or expressly indicated acceptance of testing methods alternative to laboratory animal testing, including, but not limited to, in vitro, in silico, and in chemico approaches for identifying skin sensitization hazards.
(c) (1) Notwithstanding any other law, the Attorney General, the district attorney of the county in which the violation is alleged to have occurred, or a city attorney of a city or city and county having a population in excess of 750,000 and in which the violation is alleged to have occurred, may bring a civil action for injunctive relief pursuant to this paragraph. If the court determines that the Attorney General, district attorney, or city attorney is the prevailing party in the enforcement action, the official may also recover costs, attorney fees, and a civil penalty not to exceed five thousand dollars ($5,000) for each day that each dog or each cat is used in a canine or feline toxicological experiment in violation of this section.
(2) The procedure set forth in paragraph (1) is the exclusive remedy for enforcing this section.
(d) The prohibition in subdivision (b) shall not apply to testing or experimentation conducted for the purpose of developing, manufacturing, or marketing any product intended for beneficial use in nonhuman animals, including, but not limited to, anesthesia, cancer treatment, animal vaccines, other animal medicines, flea and tick products intended to be applied to nonhuman animals, or products that are substantially the same formulation for both nonhuman animal and human markets.
SEC. 3.
 The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.